Management of newly diagnosed high‐risk and intermediate‐risk follicular lymphoma with 90Y ibritumomab tiuxetan in a phase II study

Five‐year overall survival for high‐risk Follicular Lymphoma International Prognostic Index follicular lymphoma is only approximately 50% compared with 90% for low risk. To evaluate an approach to improve upon this poor outcome, we completed an exploratory phase II trial of intensified treatment for...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hematological oncology 2018-08, Vol.36 (3), p.525-532
Hauptverfasser:	Berinstein, Neil L., Pennell, Nancy M., Weerasinghe, Rashmi, Buckstein, Rena, Piliotis, Eugenia, Imrie, Kevin R., Chodirker, Lisa, Cussen, Mary‐Anne, Miles, Ellen, Reis, Marciano D., Ghorab, Zeina, Cheung, Matthew C.
Format:	Artikel
Sprache:	eng
Schlagworte:	90Y ibritumomab tiuxetan Clinical trials Cyclophosphamide Doxorubicin follicular lymphoma Immunotherapy Lymphocytes B Lymphoma Monoclonal antibodies Myelodysplastic syndrome Neutropenia Patients Prednisone radio‐immunotherapy Remission Risk Risk management Rituximab Survival Targeted cancer therapy Thrombocytopenia Toxicity Vincristine Yttrium
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!